“In the third quarter we experienced a reduction in large capital equipment orders over $300,000, primarily in our domestic neurology business. Although some orders we expected were placed during the quarter at significantly reduced order size, other orders were not placed at all. We believe that the orders we were working on during the third quarter have not been lost, but have been merely delayed, and we expect that they will eventually be placed with Natus,” added Hawkins. “We experienced similar sales activity in late 2008 and early 2009 and then saw those delayed orders placed in following quarters.”

“We look forward to capitalizing on the opportunity that recently acquired Embla Systems brings to our neurology business as we are now a leader in the growing worldwide market for diagnostic sleep products,” added Hawkins. “We expect the Embla acquisition to be accretive to our earnings in 2012, adding approximately $0.08 to non-GAAP earnings per share.”

As of September 30, 2011, the Company had cash, cash equivalents, and short-term investments of $30.8 million, stockholders' equity of approximately $275 million, and working capital of approximately $89 million.

Financial Guidance

Natus updated its 2011 financial guidance. For the full year 2011, the Company expects to report revenue of approximately $234 million and non-GAAP earnings per share of approximately $0.48.

For the fourth quarter 2011, the Company expects to report revenue of approximately $65 million and non-GAAP earnings per share of approximately $0.15. This compares to revenue of $63.2 million and non-GAAP earnings per share of $0.24 reported in the fourth quarter of 2010.

The Company's fourth quarter and full year 2011 non-GAAP earnings per share guidance excludes amortization expense associated with acquisition-related intangible assets, which the Company expects to be approximately $5.2 million and $1.3 million for the full year and fourth quarter 2011, respectively, and which the Company expects will reduce GAAP earnings per share by approximately $0.11 and $0.03 for the full year and quarter, respectively. The non-GAAP earnings per share guidance for those periods also excludes the effects of restructuring charges that the Company expects it may incur in the fourth quarter of 2011, the amount and timing of which have not yet been determined, as well as the impact any future acquisitions might have on its results of operations.

If you liked this article you might like

Natus Medical (BABY) Stock Surges on Q3 Results, Guidance

Natus Medical (BABY) Stock Drops on Downbeat Q3 Forecast

Natus Medical (BABY) Is Today's Dead Cat Bounce Stock

Natus Medical (BABY) Stock Plunges on Preliminary Q1 Revenue

Today's Strong And Under The Radar Stock: Natus Medical (BABY)